From f29d22f6b2d372dbccc98fa3d1ad86978402b83d Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:55:28 +0000 Subject: [PATCH] pipeline: archive 1 source(s) post-merge Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...bolic-treatment-control-rates-1999-2023.md | 57 +++++++++++++++++++ 1 file changed, 57 insertions(+) create mode 100644 inbox/archive/health/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md diff --git a/inbox/archive/health/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md b/inbox/archive/health/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md new file mode 100644 index 00000000..6bfb53cb --- /dev/null +++ b/inbox/archive/health/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md @@ -0,0 +1,57 @@ +--- +type: source +title: "Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999–2023" +author: "JACC study authors (multiple)" +url: https://www.jacc.org/doi/10.1016/j.jacc.2025.09.1607 +date: 2025-10-01 +domain: health +secondary_domains: [] +format: journal-article +status: processed +priority: high +tags: [hypertension, treatment-adherence, control-rates, cardiometabolic, diabetes, hyperlipidemia, United-States, SDOH, behavioral-health, JACC] +--- + +## Content + +**JACC longitudinal study** tracking prevalence, treatment, and CONTROL of hypertension, diabetes, and hyperlipidemia in US adults from 1999–2023. + +**Key findings:** + +**Hypertension:** +- Affects **1 in 2 US adults** under 2017 ACC/AHA criteria +- Prevalence: **23.4%** ages 18–39, **52.5%** ages 40–59, **71.6%** ages 60+ +- **Little change in prevalence between 2009 and 2023** despite decades of awareness campaigns +- Among treated patients: only **23.4%** (95% CI: 21.5%-25.2%) achieved BP control in 2021–2023 by updated criteria + +**Cardiometabolic triple (hypertension + diabetes + hyperlipidemia):** +- "Treatment and control of these conditions improved during the 2000s, but progress has **plateaued in subsequent years**" +- "The proportion of individuals with hypertension, diabetes, and hyperlipidemia achieving control of all 3 conditions **did not exceed 30%** at any point during the study period" + +**Implication:** +Despite the availability of effective generic medications for all three conditions (antihypertensives since 1980s, statins since late 1990s/generics, metformin/sulfonylureas for diabetes), the US healthcare system consistently fails to achieve BP, lipid, and glycemic control simultaneously in the most at-risk patients. + +## Agent Notes + +**Why this matters:** This is the companion to the JACC CVD mortality trends archive. While the mortality archive shows WHAT happened (hypertension mortality doubled), this archive explains WHY: treatment and control rates have stagnated at very low levels despite effective, affordable drugs. Only 23.4% of treated hypertensives achieve BP control. This is the clinical face of Belief 2's "80-90% non-clinical" thesis — drugs are prescribed, but the non-clinical factors (medication adherence, food environment, lifestyle, social stress, healthcare access and continuity) overwhelm the pharmacological intervention. + +**What surprised me:** The 23.4% control rate is shockingly low. I had assumed statin success and antihypertensive effectiveness would translate to better population-level control. The fact that we've had affordable antihypertensives for 30-40 years and only 23.4% of treated patients achieve control suggests this is a deeply structural problem, not a drug availability problem. + +**What I expected but didn't find:** Evidence that control rates are improving meaningfully post-2020 with telehealth expansion, remote BP monitoring, and care management programs. The data through 2023 shows stagnation, not improvement. + +**KB connections:** +- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — this is the clinical-trial-level evidence for the 80-90% claim: 76.6% treatment failure despite effective drugs +- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] — the SDOH screening/action gap explains why these patients aren't being treated at the SDOH level +- social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day — social isolation → adherence failure → treatment non-control +- Big Food companies engineer addictive products by hacking evolutionary reward pathways — food environment → persistent hypertension despite medication + +**Extraction hints:** +- "Only 23.4% of treated US hypertensives achieved blood pressure control in 2021-2023, and the proportion simultaneously controlling hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023, demonstrating that pharmacological availability is not the binding constraint in cardiometabolic disease management" +- This claim should be paired with the hypertension mortality doubling claim — cause (treatment failure) and effect (doubled mortality) are in two separate archives + +**Context:** JACC study published October 2025, using NHANES longitudinal survey data. NHANES is the gold standard for US health surveillance — nationally representative, continuous since 1999. The 2021-2023 data is the most recent available. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] +WHY ARCHIVED: Provides the clinical-operational evidence for Belief 2 — drugs that work are not achieving outcomes at population level. The 23.4% control rate is the single most striking number for the "medicine fails despite availability" argument. +EXTRACTION HINT: Extract as a claim about cardiometabolic risk factor control failure, explicitly framing the 23.4% control rate as evidence that behavioral/SDOH barriers overwhelm pharmacological availability. Extract alongside the hypertension mortality doubling claim (queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md) — they form a cause/effect pair.